$SGRY Surgery Partners — HealthSpan Partners (affiliated with Bon Secours Mercy Health) to buy Surgery Partners in an all-cash deal — $23.50 per share, enterprise value about $5.7B — Bain Capital, owns about 39%, rolls over its shares and backs the deal — Expected to close Q1 2027, needs shareholder and regulatory approval, stock gets delisted from Nasdaq Not financial advice.

$PRSO Peraso — Signed a $10M private placement with NantCapital, closing around Oct 28 — Priced at $0.5034 per share with warrants, strike $0.3784, two year term — Money goes to working capital and drone communications built on its 60 GHz tech — Nant gets board seats, Dr. Patrick Soon-Shiong joins — Risk flag: heavy dilution, going concern doubt, Nasdaq compliance issues Not financial advice.

$ACB $CURLF Aurora Cannabis, Curaleaf — Alberta Securities Commission dismissed Curaleaf's application to halt Aurora's at-the-market program — Aurora says it last used the ATM on Aug 18 and has not touched it during the hostile bid — Board still unanimously says reject the revised bid, take no action, and withdraw any tendered shares — Aurora says the bid undervalues the company and is weighing other strategic alternatives Not financial advice.

$IQST IQSTEL — Closed up to $3M in two-year senior secured non-convertible notes, plus pre-funded warrants for up to 420,000 shares — Funds the planned 51% buy of Ultranet, a West African telecom platform with $130.9M 2025 revenue, up 30%, and $4.6M net income — Notes carry 18% interest paid monthly — Risk flag: purchase agreement not signed yet, closing targeted mid Q1 2027, no operator deals signed for the microdrama service Not financial advice.

$BEAT HeartBeam — FDA accepted its 3D ECG heart attack assessment tech into the TAP Pilot program — Comes weeks after Breakthrough Device Designation earlier this month — Pivotal study design talks with the FDA coming, patient enrollment expected Q1 2027 — Risk flag: not cleared for heart attack detection yet, TAP does not guarantee FDA authorization or coverage Not financial advice.

$SHFS Safe Harbor Financial — Signed a non-binding term sheet to merge with creator-economy firm Opifex Media, new name to come — Opifex holders would own 85% of the combined company, Safe Harbor holders 15% — Nasdaq gave a second compliance period through April 19, 2027 for the $1 bid price rule — Risk flag: reverse split likely, heavy dilution, 45-day exclusivity, no definitive agreement yet Not financial advice.

$OPTT $SRTM Ocean Power Technologies, Stratum Holdings — Signed a non-binding LOI to demo offshore data centers powered by wave, wind and solar — OPT would license PowerBuoy patents and provide prototype buoys, Stratum would bring GPUs including NVIDIA B300s — Stratum would pay OPT a monthly retainer — Risk flag: no definitive agreements yet, either side can walk, cooling savings not proven Not financial advice.

$NXTS Nexentis Technologies — Subsidiary MitoCareX finished the first computational screening stage of its AI drug discovery deal with Boltz — Predictions are preliminary and not tested in the lab yet — MitoCareX keeps control of its discovery programs and any candidates — Risk flag: no guarantee any compound moves into preclinical or clinical development Not financial advice.

$SPCX SpaceX — Signed a binding commitment for a GPU finance lease with an Apollo-managed entity — About $40B in aggregate principal payments Not financial advice.

$STEM Stem Inc — Board started a formal review of strategic alternatives — Options include asset sales, a sale of the company, merger, refinancing or recapitalization — Hired Guggenheim as financial advisor, no timetable set — Q3 results on Nov 5 after the close, call at 5:00 PM ET — Risk flag: no guarantee of any deal, no updates until the board approves a transaction Not financial advice.

$VBIO Valion Bio — Got unsolicited acquisition interest in its CDMO unit Velocity Bioworks — In preliminary talks with the interested parties, hired an investment bank to advise the board — Wants to keep production rights for lead drug Entolimod in any deal — Risk flag: no commitment to a sale, no guarantee of a definitive agreement, no more updates planned unless a deal is signed Not financial advice.

$ARTL Artelo Biosciences — Will present ART26.12 data at the World Congress on Pain in Bangkok on Oct 29 — ART26.12 is an oral non-opioid pain drug, first selective FABP5 inhibitor in human trials, aimed at chemo-induced nerve pain — Phase 1 single dose study showed no serious adverse events and a wide safety margin — Phase 1 multiple dose study set to start Q4 2026 Not financial advice.

$XXII 22nd Century Group — Added 100's and Menthol (Green) varieties to Pinnacle Pure, now 6 SKUs total — Pinnacle Pure is a tobacco and water cigarette, launched in Q2 2026 at about 1,500 retail outlets with its launch partner — New 100's and Menthol start shipping in December 2026 — Risk flag: no sales numbers given, still early rollout Not financial advice.

$XNCR Xencor — Picked 400 mcg/kg as the proposed Phase 3 dose for XmAb819 in advanced clear cell kidney cancer — At that dose, confirmed ORR 45.5%, unconfirmed ORR 55%, six-month PFS 82% — Generally well tolerated in heavily pretreated patients, all had prior PD-(L)1 and VEGFR TKI — Plans to talk accelerated approval with the FDA in 1H27 and run a global randomized study vs tivozanib Not financial advice.

$OPTT $SRTM Ocean Power Technologies, Stratum Holdings — Signed a non-binding LOI to demo offshore data centers powered by wave, wind and solar — OPT would license PowerBuoy patents and provide prototype buoys, Stratum would bring GPUs including NVIDIA B300s — Stratum would pay OPT a monthly retainer — Risk flag: no definitive agreements yet, either side can walk, cooling savings not proven Not financial advice.

$CLRO Cortigent merger expected to price and close in October — Vivani Medical says its Cortigent merger with a ClearOne unit is expected to price and close in October 2026 — Cortigent becomes a wholly owned subsidiary of ClearOne once the deal closes — Timeline now pinned to October, pricing terms still to come — Deal still subject to closing conditions Not financial advice.

$CLRO ClearOne — Closed Friday at $3.25, up 69.27%, range $1.97 to $4.685, down 13.23% premarket — Pending merger with Cortigent (Vivani Medical sub) needs an effective S-1, a $10M-$15M offering and Nasdaq listing approval — Cash was $75K as of June 30, going concern doubt, no revenue from continuing ops since the Biamp sale — Risk flag: dilution, 12.5M merger shares approved, 1-for-15 reverse split already done in June 2025 Not financial advice.

$CANF Can-Fite BioPharma — Presented final Phase 2a data for namodenoson in pancreatic cancer at ESMO — Hit primary safety endpoint, only Grade 1-2 related events, none Grade 3 or higher — Third-line patients who lived past 2 months: median OS 6.28 months, median PFS 2.27 months — Risk flag: only 20 patients, no control arm, and the subgroup was picked by survival Not financial advice.

$VZ Verizon Communications Q3 earnings — EPS $1.31 vs $1.27 est, beat — Revenue $34.3B vs $34.85B est, miss — EPS up 8% YoY and up 1% QoQ — Revenue up 1% YoY Not financial advice.

$META Meta Platforms — Launched about $35B in offerings: $22.5B Class A common via forward sale agreements and $12.5B mandatory convertible preferred — Plans a $60B at-the-market program on Class C stock, expected to start Q1 2027 — $NVDA, $AMD and $AVGO showed interest in up to $5B of the common — 2026 capex guided to $135B-$145B Not financial advice.